Geron Corp's Rytelo launch & robust pipeline offer a compelling investment opportunity, despite stock challenges. Click here ...

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

Saeed Sadeghi, MD, discusses the findings on transfusion independence achieved with treatment for patients with low-risk ...

as well as in anaemia failing an erythropoiesis stimulating agent that requires two or more RBC units over eight week in adult patients with IPSS-R myelodyplastic syndrome with ring sideroblasts ...

Moreover, while Reblozyl was only cleared for use as second-line therapy in MDS patients with ring sideroblasts – blood cells with a characteristic circle of iron deposits around their nucleus ...

This trial included patients with MDS/MPN-unclassifiable, atypical CML, MDS/MPN with ring sideroblasts and thrombocytosis, and chronic neutrophilic leukemia. These diseases fall under the category of ...

Treatment modalities in such candidates include hematopoietic growth factors, luspatercept in candidates with ring sideroblasts, epigenetic modifiers, erythrocyte transfusions, and immunosuppressive ...

1 % of blasts were identified, and an increase of medullar iron was present with no ringed sideroblasts. Immunohistochemical analysis with CD61 made micro-megakaryocytes highlighted dysplastic ...

Erythroblasts possess unique characteristics as they undergo differentiation from hematopoietic stem cells. During terminal erythropoiesis, these cells incorporate large amounts of iron in order to ...

In their original work, Xicoy et al. describe the hybrid entity of chronic myelomonocytic leukemia with ring sideroblasts and SF3B1 mutation, which is strikingly similar to the entity of MDS with low ...

The trailblazing Harvard scientist, who documented the dominance of hydrogen and helium in stars, is still inspiring ...